GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Shares Outstanding (EOP)

Xbrane Biopharma AB (OSTO:XBRANE) Shares Outstanding (EOP) : 263.0 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Xbrane Biopharma AB's shares outstanding for the quarter that ended in Dec. 2023 was 263.0 Mil.

Xbrane Biopharma AB's quarterly shares outstanding increased from Sep. 2023 (262.3 Mil) to Dec. 2023 (263.0 Mil). It means Xbrane Biopharma AB issued new shares from Sep. 2023 to Dec. 2023 .

Xbrane Biopharma AB's annual shares outstanding increased from Dec. 2022 (242.6 Mil) to Dec. 2023 (263.0 Mil). It means Xbrane Biopharma AB issued new shares from Dec. 2022 to Dec. 2023 .


Xbrane Biopharma AB Shares Outstanding (EOP) Historical Data

The historical data trend for Xbrane Biopharma AB's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Shares Outstanding (EOP) Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 135.98 195.83 220.88 242.63 262.96

Xbrane Biopharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 242.63 242.63 257.71 262.26 262.96

Competitive Comparison of Xbrane Biopharma AB's Shares Outstanding (EOP)

For the Biotechnology subindustry, Xbrane Biopharma AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Shares Outstanding (EOP) falls into.



Xbrane Biopharma AB Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Xbrane Biopharma AB  (OSTO:XBRANE) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Xbrane Biopharma AB Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines